Harbor Capital Advisors Inc. Sells 97,362 Shares of OrthoPediatrics Corp. (NASDAQ:KIDS)

Harbor Capital Advisors Inc. decreased its position in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 38.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 154,226 shares of the company's stock after selling 97,362 shares during the period. Harbor Capital Advisors Inc. owned about 0.64% of OrthoPediatrics worth $3,799,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new position in shares of OrthoPediatrics during the 4th quarter valued at $79,000. AlphaCentric Advisors LLC bought a new stake in OrthoPediatrics in the 4th quarter valued at about $171,000. Wells Fargo & Company MN lifted its holdings in OrthoPediatrics by 31.1% during the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock valued at $228,000 after purchasing an additional 2,338 shares during the last quarter. GAMMA Investing LLC lifted its holdings in OrthoPediatrics by 4,618.2% during the first quarter. GAMMA Investing LLC now owns 10,616 shares of the company's stock valued at $261,000 after purchasing an additional 10,391 shares during the last quarter. Finally, HighTower Advisors LLC bought a new position in OrthoPediatrics during the fourth quarter worth about $268,000. 69.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on KIDS shares. Lake Street Capital started coverage on shares of OrthoPediatrics in a research note on Monday, April 7th. They set a "buy" rating and a $37.00 price target on the stock. Stifel Nicolaus cut their price target on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, March 5th. Needham & Company LLC reiterated a "buy" rating and set a $42.00 price objective on shares of OrthoPediatrics in a research note on Thursday, May 8th. Wall Street Zen cut OrthoPediatrics from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Finally, Truist Financial cut their target price on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research note on Friday, April 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.83.

Insider Activity at OrthoPediatrics

In other news, insider Gregory A. Odle sold 5,359 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $133,224.74. Following the completion of the transaction, the insider now directly owns 148,788 shares in the company, valued at approximately $3,698,869.68. This represents a 3.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $132,006.60. Following the transaction, the general counsel now owns 110,767 shares in the company, valued at $2,753,667.62. This trade represents a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,732 shares of company stock valued at $589,978 over the last three months. 32.70% of the stock is owned by corporate insiders.

OrthoPediatrics Price Performance

Shares of OrthoPediatrics stock traded down $0.56 during trading on Friday, hitting $21.16. The stock had a trading volume of 108,387 shares, compared to its average volume of 200,600. The firm has a market cap of $513.91 million, a price-to-earnings ratio of -17.20 and a beta of 1.08. OrthoPediatrics Corp. has a 12 month low of $19.52 and a 12 month high of $35.99. The business's 50-day moving average is $21.51 and its 200 day moving average is $23.31. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.41 million during the quarter, compared to the consensus estimate of $51.68 million. As a group, sell-side analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.